Literature DB >> 15848189

Phoslactomycin targets cysteine-269 of the protein phosphatase 2A catalytic subunit in cells.

Takayuki Teruya1, Siro Simizu, Naoki Kanoh, Hiroyuki Osada.   

Abstract

According to the chemical genetic approach, small molecules that bind directly to proteins are used to analyze protein function, thereby enabling the elucidation of complex mechanisms in mammal cells. Thus, it is very important to identify the molecular targets of compounds that induce a unique phenotype in a target cell. Phoslactomycin A (PLMA) is known to be a potent inhibitor of protein Ser/Thr phosphatase 2A (PP2A); however, the inhibitory mechanism of PP2A by PLMA has not yet been elucidated. Here, we demonstrated that PLMA directly binds to the PP2A catalytic subunit (PP2Ac) in cells by using biotinylated PLMA, and the PLMA-binding site was identified as the Cys-269 residue of PP2Ac. Moreover, we revealed that the Cys-269 contributes to the potent inhibition of PP2Ac activity by PLMA. These results suggest that PLMA is a PP2A-selective inhibitor and is therefore expected to be useful for future investigation of PP2A function in cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15848189     DOI: 10.1016/j.febslet.2005.03.049

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition.

Authors:  Brian G Lawhorn; Sobhana B Boga; Scott E Wolkenberg; David A Colby; Carla-Maria Gauss; Mark R Swingle; Lauren Amable; Richard E Honkanen; Dale L Boger
Journal:  J Am Chem Soc       Date:  2006-12-27       Impact factor: 15.419

Review 2.  Synthetic Strategies Employed for the Construction of Fostriecin and Related Natural Products.

Authors:  Barry M Trost; Joshua D Knopf; Cheyenne S Brindle
Journal:  Chem Rev       Date:  2016-12-08       Impact factor: 60.622

3.  KSRP/FUBP2 Is a Binding Protein of GO-Y086, a Cytotoxic Curcumin Analogue.

Authors:  Hiroyuki Yamakoshi; Naoki Kanoh; Chieko Kudo; Atsuko Sato; Kazunori Ueda; Makoto Muroi; Shunsuke Kon; Masanobu Satake; Hisatsugu Ohori; Chikashi Ishioka; Yoshiteru Oshima; Hiroyuki Osada; Natsuko Chiba; Hiroyuki Shibata; Yoshiharu Iwabuchi
Journal:  ACS Med Chem Lett       Date:  2010-06-04       Impact factor: 4.345

Review 4.  Genetic manipulation of the biosynthetic process leading to phoslactomycins, potent protein phosphatase 2A inhibitors.

Authors:  Mohini Ghatge; Nadaraj Palaniappan; Suparna Das Choudhuri; Kevin Reynolds
Journal:  J Ind Microbiol Biotechnol       Date:  2006-04-12       Impact factor: 3.346

5.  cis-Delta(2,3)-double bond of phoslactomycins is generated by a post-PKS tailoring enzyme.

Authors:  Nadaraj Palaniappan; Mamoun M Alhamadsheh; Kevin A Reynolds
Journal:  J Am Chem Soc       Date:  2008-08-21       Impact factor: 15.419

6.  Application of a newly identified and characterized 18-o-acyltransferase in chemoenzymatic synthesis of selected natural and nonnatural bioactive derivatives of phoslactomycins.

Authors:  Mohini S Ghatge; Nadaraj Palaniappan; Ma'moun M Alhamadsheh; Jessica DiBari; Kevin A Reynolds
Journal:  Appl Environ Microbiol       Date:  2009-03-20       Impact factor: 4.792

Review 7.  Regulation of Cardiac PKA Signaling by cAMP and Oxidants.

Authors:  Friederike Cuello; Friedrich W Herberg; Konstantina Stathopoulou; Philipp Henning; Simon Diering
Journal:  Antioxidants (Basel)       Date:  2021-04-24

8.  Preparation of an advanced intermediate for the synthesis of leustroducsins and phoslactomycins by heterocycloaddition.

Authors:  Anaïs Rousseau; Guillaume Vincent; Cyrille Kouklovsky
Journal:  Beilstein J Org Chem       Date:  2022-10-04       Impact factor: 2.544

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.